Evidence map›Paper›PMID 32853096›Full record

ArticleCirculation research2020

Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?

John D Martin, Dan G Duda, Rakesh K Jain

Open access · bronzeAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

John D MartinFrom NanoCarrier Co, Ltd, Kashiwa, Chiba, Japan (J.D.M.).
Dan G Dudathe Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (D.G.D., R.K.J.).
Rakesh K Jainthe Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (D.G.D., R.K.J.).
Massachusetts General Hospital · USNanoCarrier (Japan) · JP

Funding

Dissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7M
Reprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9M
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2M
NCI NIH HHS R01 CA208205NCI NIH HHS R35 CA197743NCI NIH HHS U01 CA224348
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsVascular Endothelial Growth Factor AApoptosisEndothelial CellsHumansProtein Phosphatase 2Vascular RemodelingProtein Phosphatase 2Vascular Endothelial Growth Factor Abasement membranebiomarkerdisease progressionEditorialshypoxiapericytes

Identifiers

PMID32853096
PMCPMC7462096
OpenAlexW3080783848

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.